FDA
-
-
-
-
-
-
-
Arrowhead Pharmaceuticals Acquires FDA Priority Review Voucher
-
-
-
-
-
-
-
Arrowhead Pharmaceuticals Presents New Positive Clinical Cardiometabolic Data at the 94th European Atherosclerosis Society (EAS) Congress
-
-
-
-
-
-
-
Arrowhead Pharmaceuticals Presents New Long-Term Efficacy and Safety Data for Plozasiran Across a Spectrum of Hypertriglyceridemia at the American College of Cardiology’s 75th Annual Scientific Sess
-
-
-
-
-
-
-
Arrowhead Pharmaceuticals Announces Health Canada Approval of REDEMPLO™ (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)
-
-
-
-
-
-
-
TD Cowen on Arrowhead Pharma (ARWR): 'Momentum Is Strong; Buy'
-
-
-
-
-
-
-
Arrowhead files lawsuit against Ionis over plozasiran patent dispute
-
-
-
-
-
-
-
Arrowhead Pharmaceuticals Reports Fiscal 2025 Second Quarter Results
-
329,758 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

